English

Bioretec Ltd – Managers’ transactions

Report this content

Bioretec Ltd      Managers’ transactions   9 May 2022 at 16.00 p.m. EEST

 Bioretec Oy - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Päivi Malinen

Position: Member of the Board/Deputy member

Issuer: Bioretec Oy

LEI: 7437008736AG7HY51K13

Notification type: INITIAL NOTIFICATION

Reference number: 14583/5/6

____________________________________________

Transaction date: 2022-05-09

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Instrument name: Bioretec Oy, optio-ohjelma 2020-1, B-C

Nature of the transaction: ACCEPTANCE OF A STOCK OPTION

Transaction details

(1): Volume: 300000 Unit price: 0 EUR

(2): Volume: 300000 Unit price: 0 EUR

Aggregated transactions

(2): Volume: 600000 Volume weighted average price: 0 EUR

Further enquiries

Timo Lehtonen, CEO, tel. +358 50 433 8493
Johanna Salko, CFO, tel. +358 40 754 8172
Certified Adviser: Nordic Certified Adviser AB, p. +46 70 551 67 29


Information about Bioretec

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of bioresorbable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong bioresorbable materials for enhanced surgical outcomes. The RemeOs™ implants are resorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. With the U.S. and EU market authorization for the first RemeOs™ product expected in 2022, Bioretec is positioning itself to enter the addressable USD 7 billion global orthopedic trauma market and become a game changer in surgical possibilities. Better Healing – Better Life. www.bioretec.com. 

Subscribe